Almost all primary liver carcinomas are broadly classified either as hepatocellular carcinoma (HCC), derived from hepatocytes, or cholangiocarcinoma (CC), arising from intrahepatic bile duct epithelium. These tumours rapidly outgrow their vascular supply and become hypoxic, resulting in the production of hypoxia inducible factors and triggering the angiogenic switch [1, 2] . The identification and regulation of factors responsible for these angiogenic processes are areas of active investigation, as these pathways could provide valuable targets for therapeutic intervention, especially in HCC in which the multikinase inhibitor sorafenib (Nexavar) is currently the standard of care for advanced HCC patients [3] [4] [5] . The vascular endothelial growth factor (VEGF) has gathered extensive attention for its role in mediating tumour angiogenesis [6] [7] [8] [9] , but recently interest in the placental growth factor (PlGF) [10] [11] [12] [13] [14] has grown. PlGF is a VEGF homologue, which is only involved in pathologic angiogenesis; therefore, its inhibition does not induce side-effects [14, 15] .
PlGF, a member of the VEGF family, is known to stimulate endothelial cell growth, migration and survival [15, 16] . It also attracts angiocompetent macrophages and bone marrow progenitor cells and determines the metastatic niche [16, 17] . Unlike VEGF, PlGF binds to VEGF receptor 1 (VEGFR1) and its coreceptors neuropilin-1 and neuropilin-2 [18] . Therefore, PlGF exerts its proangiogenic potential through two mechanisms, directly, by inducing signal transduction through its receptors [19] , and indirectly, by preventing the binding of VEGF to its decoy receptor VEGFR1 [20] . In contrast to VEGF, genetic studies have shown that PlGF is specifically involved in the pathological angiogenesis [14, 15] . Therefore, its inhibition would not affect healthy blood vessels, providing an attractive drug candidate with a good safety profile. Treatment with PlGF antibodies has shown beneficial effects in several mouse models for chronic liver disease, including portal hypertension [11] , cirrhosis [12] and HCC [13] . Its influence on CC remains unknown.
Although antiangiogenic treatment for HCC has been established as the standard of care in advanced HCC patients, its potential in CC patients is less investigated. However, the role of the Ras-Raf-Mek-Erk pathway [5] and VEGF in biliary carcinomas has already been clarified in several studies [21, 22] . Furthermore, patients with biliary cancers receiving sorafenib (Nexavar) had some therapeutic benefit. However, the severe adverse effects have forced an early stop to the phase II trial (SWOG 0514) [23] . The combination of bevacizumab and erlotinib may offer a therapeutic alternative in patients with advanced biliary cancer, but may also be limited because of the occurrence of adverse effects (NCT00356889) [24] . In addition, studies have shown that inducing an ischaemic injury by transarterial chemoembolization in HCC leads to an increased occurrence of a mixed hepatocholangiocellular tumour phenotype, emphasizing the need for new therapeutics to manage this aggressive form of primary liver cancer [25, 26] .
In a previous study, we have shown that mice containing a heterozygous mutation silencing the prolyl hydroxylase containing domain 2 (PHD2) proteins develop both HCC and CC after 25 weeks of diethylnitrosamine (DEN) administration [27] . In this study, we would like to use this model to assess whether treatment with monoclonal antibodies targeting PlGF could offer a therapeutic option in mice with HCC and CC. 
Materials and methods
Genotyping PHD2 + /mice were obtained from the Vesalius Research facility (KU Leuven, Belgium). A heterogenic couple was used for breeding and the offspring was genotyped with the following primers at a concentration of 10 mmol/l: ACCTAT GATCTCAGCATTTGGGAG; TCAGGACAGTGAAGCC TAGAAACT and AAATTCTAATCGTAGCTGATGTGA GC; the latter being used as a reversed primer in both the wild-type and the mutant reaction. The PCR product was run on a 1.5% agarose gel and heterozygous mice were distinguished by the appearance of PCR bands at 380 and 340 bp.
Hepatocellular carcinoma and cholangiocarcinoma induction
Five-week-old heterozygous PHD2 knockout male mice (PHD2 + / -) with an 129S2/SvPasCrl background received intraperitoneal injections once a week with DEN (Sigma-Aldrich, Bornem, Belgium) or saline as described previously [27, 28] . After 25 weeks, mice developed both HCC and CC. The Ethical Committee of experimental animals at the Faculty of Medicine and Health Sciences, Ghent University, Belgium, approved the protocol.
Placental growth factor inhibition
A murine anti-PlGF monoclonal antibody (clone 5D11D4; referred to as aPlGF) that specifically recognizes mouse PlGF-2 was obtained from Thrombogenics (Leuven, Belgium). Mice that received DEN for 25 weeks were subsequently treated with 25 mg/kg aPlGF (2 Â /week, n = 8) for 5 weeks or IgG (2 Â /week, n = 8) as a control substance. During the treatment, mortality was noted to obtain survival curves.
Sampling and histology
Animals were killed after administration of DEN for 25 weeks followed subsequently by 5 weeks of treatment [aPlGF (n = 6) or IgG (n = 5)] with isoflurane (Forene, Abbott, Hoofddorp, the Netherlands) anaesthesia; blood was obtained from the ophthalmic artery. The liver was prelevated first, and after washing with sterile 5% NaCl, it was cut into 5-mm pieces for macroscopic quantification of the number of macroscopic (> 1 mm) hepatic tumours. Subsequently, all organs were evaluated and sampled in 4% phosphate buffered formaldehyde (ref:
4078.9020; Klinipath, Olen, Belgium) and embedded in paraffin, as previously described [28] . Tumour lesions and nontumour tissue were separately collected and snap frozen in liquid nitrogen for subsequent analysis. Haematoxylineosin staining (H&E) was performed to evaluate the morphological changes inflicted by the treatment with aPlGF. Sirius Red staining was used to determine the Metavir score for fibrosis and to indirectly score the burden of CC lesions as it is closely linked to cholangiofibrosis. CC lesions were also staged by distinguishing normal bile ducts (stage 0), cholangioma (stage 1), mixed cholangioma and CC (stage 2) and CC (stage 3), as previously described [29] .
Reticulin staining was performed to identify HCC nodules. The HCC burden was quantified by multiplying the size by the number of tumours in 10 random regions of interest of 376 665.37 mm 2 . Tumour area was calculated by manually selecting the tumour's perimeter using the Olympus CellD software (Olympus, Zoeterwoude, the Netherlands).
Stainings were performed using standard histology protocols and evaluated by an experienced pathologist.
Immunohistochemistry
Immunohistochemistry was used to quantify protein levels inside hepatic tumours and in surrounding nontumour tissue. As a marker for angiogenesis, a monoclonal antibody was used targeting CD105 or endoglin (ref: AF1320; R&D systems, Abingdon, UK) [30] . Intercapillary distance was used as a marker for microvessel density by measuring the average distance between vessels in HCC nodules on CD105-stained slides. F4/80 (ref: MCA497G; AbD serotec, Dusseldorf, Germany) was used as a pan-macrophage marker. CD206 and CD163 were used as M2-macrophage markers, whereas HLA-DR was used as an M1-macrophage marker. Stainings were performed as described in Table 1 and quantified using Olympus CellD software. Belgium). Genes and corresponding primer sets are listed in Table 2 . The efficiency is calculated from the slope of the standard curve according to the following formula: E = 10 (-1/slope) -1. All reactions were run in duplicate and normalized to a set of reference genes that showed stable expression in all samples. The comparative C t method was used to determine the number of transcripts.
Statistics
Data were analysed using SPSS 19 (SPSS Inc., Chicago, Illinois, USA). After testing for normality and homoscedasticity, data were either subjected to Student's t-test or Mann-Whitney U-test. A P-value of less than 0.05 was considered statistically significant. Data mentioned in the manuscript are expressed as averages±SEM. n = 6 for aPlGF and n = 5 for IgG in all the experiments. 
Results

Macroscopic evaluation
A significant increase in weight (P < 0.05) was observed in DEN-induced PHD2 + /mice treated with aPlGF (25.37±0.95 g) compared with the IgG controls (22.16± 0.46 g; Fig. 1 ). Macroscopic evaluation of the liver revealed that DEN-induced PHD2 + /mice treated with aPlGF had less hepatic tumours (7.80±2.20 liver tumours) compared with those who received control (22.17±4.22 liver tumours). No significant difference was seen in relative liver or spleen weight (Fig. 1) . Treatment with aPlGF also did not significantly improve survival (Fig. 1) . Although DEN-injected IgG mice did not show any extrahepatic metastasis, two out of eight (25%) aPlGF-treated mice developed tumours in the lungs and vesicula seminalis. However, this was not significant.
Microscopic evaluation
Hepatocellular carcinoma H&E staining showed that all PHD2 + /mice developed HCC. Besides HCC lesions, small-cell dysplasia was frequently found throughout the liver, and readily distinguishable nodules of hepatic neoplasia were seen in both treatment types (Table 3 ). These nodules were confirmed as HCC using reticulin and H&E staining. Treatment with aPlGF significantly decreased both the number (aPlGF 3.8±0.49 vs. IgG 8.5±0.65; P < 0.001) and the size (aPlGF 467 000±64 000 mm 2 vs. IgG 5 633 000±1 480 000 mm 2 ; P < 0.001) of HCC lesions. Consequently, the tumour burden was significantly decreased (P < 0.01; Fig. 2 ; Table 3 ).
Cholangiocarcinoma H&E staining showed that all PHD2 + /mice had developed CC (Fig. 3) . Evaluation of CC stage revealed that aPlGF-treated mice were more likely to show biliary hyperplastic and cholangioma lesions lined by flattened epithelium, whereas control-treated livers had a mixed occurrence of cholangioma and CC, characterized by the appearance of some goblet-like cells as well as flattened epithelium and biliary dysplasia (Fig. 3 ). An increased uptake of Sirius Red was seen in the CC lesions (Fig. 3) . Measurement of the percentage of Sirius Red staining confirmed that there was a decrease in cholangiofibrosis in mice that received aPlGF compared with mice that received IgG as a control (Fig. 2) .
Inflammation and fibrosis
Fibrosis induced by chronic administration of DEN was significantly decreased (P < 0.05) by the PlGF antibodies (Metavir scores: aPlGF 1.27±0.40 vs. IgG 2.73±0.07; Fig. 4 ). Macrophage recruitment, measured using F4/80 staining, was significantly decreased in surrounding tissue of aPlGF-treated mice (aPlGF 4.02±1.50% F4/80 vs. IgG 7.02±0.52% F4/80; P < 0.05; Fig. 4 ). No significant difference was seen in percentage of F4/80 staining the HCC lesions, but a significant increase took place in the CC lesions ( Fig. 4) . aPlGF significantly decreased infiltration of CD206 + macrophages (M2 marker) in nontumour tissues and in CC lesions, however a nonsignificant trend towards increase was seen in HCC lesions (Fig. 5 ). No significant difference was seen in HLA-DR (M1 marker) or in CD163 (M2 marker; Fig. 6 ).
Angiogenesis
No significant difference was seen between aPlGF-treated and IgG-treated mice (Fig. 3 ). Yet, aPlGF-treated HCC lesions showed a trend towards lower vascularization, measured by determining both the intercapillary distances and the percentages of endoglin (CD105) staining inside the hepatocellular tumours ( Fig. 7) . Treatment with aPlGF significantly decreased the vascularization of fibrotic, nontumour tissue surrounding the CC and HCC lesions.
Vegf had a significantly higher expression in aPlGF-treated tumours, which was not seen in the surrounding tissue ( Fig. 8 ). However, this increase was not translated into protein levels, as no significant difference in VEGF concentration was seen in tumour and nontumour tissues between aPlGF-treated and IgG-treated livers (Fig. 7) . Furthermore, treatment with aPlGF significantly decreased serum levels of VEGF compared with treatment with IgG controls (aPlGF 206.35±12.70 pg/ml vs. IgG 528.94± 210.56 pg/ml; P < 0.05; Fig. 7 ).
Metastasis
Expression levels of the prometastatic markers Mmp9, Itgav and Icam showed that aPlGF significantly decreased the prometastatic potential. In the tissue surrounding the tumour, a significant decrease in Itgav (P < 0.05) and Icam (P < 0.05) was seen, whereas a trend towards lower Mmp9 expression was observed ( Fig. 9 ). Inside tumour lesions, a significant 
Discussion
Treatment with PlGF antibodies has shown beneficial effects in several mouse models for chronic liver disease, including portal hypertension [11] , cirrhosis [12] and HCC [13] ; yet, its influence on CC remains unknown.
In a previous study, we have shown that heterozygous PHD2 knockout mice develop both HCC and CC after chronic administration of DEN [27] . Therefore, we used this model to assess the effect of monoclonal antibodies targeting PlGF on the progression of HCC and CC.
Treatment with PlGF antibodies significantly improved tumour burden, both of HCC and of CC. This might be due to inhibition of the proliferative effect of PlGF on macrophages [16, 31] and endothelial cells [14, 16] ; however, further investigation is needed to assess the exact mechanism of how (anti)PlGF influences hepatocarcinogenesis. As PlGF is known to affect the tumour-associated macrophage niche [17] , we assessed the M1 and M2 macrophages using three markers (HLA-DR, CD206 and CD163). A significant decrease in CD206 + macrophages was observed in CC lesions, suggesting a possible reduction in M2-macrophage infiltration. These macrophages are known to have a protumoural effect and could possibly enhance metastasis. Recent studies using microarrays and immunohistochemistry have shown that PlGF expression is increased in Japanese nonfluke-related CC [32] and that its expression is correlated with loss of liver-intestine cadherine [33] , which may reflect that PlGF can be correlated with development of metastasis in CC. In our study, RNA analysis showed a significant decrease in the prometastatic markers Itgav and Icam in the tissue surrounding the tumour. However, in the tumour tissue only Icam was significantly decreased, whereas there was a trend towards higher Itgav expression. In addition, the occurrence of extrahepatic tumours in some aPlGFtreated mice needs further investigation in mouse models more suitable for metastasis research.
Possibly because of the small sample size, only a positive trend but no significant difference was observed between vascularization in aPlGF-treated and IgG-treated HCC lesions; however, previous studies have shown that PlGF antibodies decrease tumour induced vascularization in and around HCC lesions [13] . Several studies have shown that targeting the VEGF pathway often induces 'angiogenic escape' by upregulating other angiogenic factors [34, 35] . Therefore, we have measured expression levels of VEGF, as angiogenic escape of PlGF treatment is likely to act through this factor [15] . Nevertheless, no significant differences were seen in protein VEGF levels after treatment with aPlGF. However, RNA levels of Vegf showed a significant upregulation in tumour tissue. Thus, a longer follow-up study would be needed to confirm that long-term inhibition of PlGF does not induce angiogenic escape through VEGF. Treatment with aPlGF did significantly decrease the serum levels of VEGF, possibly due to an increased binding to its decoy receptor VEGFR1.
Conclusion
This study has shown for the first time that inhibition of PlGF decreases HCC and CC burden in an orthotopic DEN-induced mouse model for these primary liver tumours. Unlike VEGF, genetic studies have shown that PlGF is specifically involved in the pathological angiogenesis [14, 15] , thus providing an attractive drug candidate against CC and HCC with a good safety profile. As clinical studies using sorafenib (Nexavar) for treatment of CC have shown that it provides only minimal therapeutic benefit, accompanied by severe adverse effects (SWOG 0514) [23] , the use of monoclonal antibodies targeting PlGF can serve as a potential systemic treatment method in patients having this aggressive liver tumour. landers 
